Chargé E

NEW YORK and PARIS, July 25, 2023 /PRNewswire/ -- Hivebrite, the leading community management and engagement platform, has announced a new partnership with moka.care, the online mental health platform, to provide support for its employees in the European Union. The partnership aims to enhance Hivebrite's effort to protect its employees' mental health and well-being.In the United States, Hivebrite already offers its employees an Employee Assistance Program (EAP) through Trinet and FEI Workforce Resilience. The new partnership brings the same mental health support to its employees in the European Union, which will help them to access mental health resources and support in their local language.The partnership with moka.care will enhance Hivebrite's effort to protect its employees' mental health and well-being. Tweet thisThe new online platform offered by moka.care includes features such as teleconsultations with psychotherapists and psychiatrists, access to self-help programs and a chatbot for immediate support. Additionally, moka.care's platform offers frequent educational content and personalized behavioral support to employees."We are thrilled to partner with moka.care in offering our EU employees access to essential mental health support and resources. Protecting and promoting employee well-being as well as personal development is a constant commitment at Hivebrite," said Jean Hamon, CEO of Hivebrite.With this new collaboration, Hivebrite has taken an essential step towards providing its global workforce with a workplace that prioritizes their mental health and well-being and takes into account their diversity

At least 1 in 5 people will experience mental illness at any time, yet for many, treatment is prohibitive due to long-waiting lists for mental health professionals, hospital bed shortages, and medication that comes with adverse side effects.The notion of mental wellbeing has widened to include social determinants of health and emotional wellbeing, with as much effort put into the cause and prevention of illness and treatment.Mental health startups are looking at mental wellness from various angles, including leading research into new pharmacological therapies, personalised diagnostics and treatments, to telehealth. The approach is evidence lead and solution-focused, underpinned by valuable partnerships with clinicians and academic researchers to create life-changing results.And investments are booming, let's take a look at the most funded companies over the last few years:atai Life Sciences (Germany)atai is a biopharmaceutical company that leverages a decentralised platform approach to incubate and accelerate the development of highly effective pharmaceutical treatments for complex mental health conditions such as depression, anxiety, schizophrenia, and addiction.An example of its work is a clinical study into PCN-101 (R-ketamine) as an alternative treatment to slow-acting antidepressants and treatment-resistant depression.The company is also exploring the use of RL-007 to treat the cognitive impairments associated with conventional treatment for schizophrenia is also underway. RL-007 (a GABA / nicotinic modulator) is a small molecule that modulates the excitatory/inhibitory balance in the brain to improve learning and memory.atai Life Sciences has raised $522.1 million in funding over rounds. It most recently raised Series D funding ($225 million) from an IPO.Alan (France)Alan is a one-stop employee health service offering "personalised access to information, proactive care, care delivery, payment and post-care."Following the mental health app Jour acquisition in 2021, the company launched Alan Mind app to broaden mental health and wellbeing offerings. The app takes a comprehensive look at mental health, from preventing psychosocial risks to ongoing individual support.Alan raised €493 million, including €183 million in Series E in 2022.Compass Pathways (UK)Compass Pathways is a mental health care company dedicated to accelerating patient access to evidence-based pharmaceutical innovation in mental health.The Company pioneers the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, for use in treatment-resistant depression (TRD), is administered in conjunction with psychological support. It completed a phase 2b clinical trial of psilocybin therapy for TRD in 22 sites across Europe and North America was the largest randomised, controlled, double-blind psilocybin therapy clinical trial ever conducted.Patients who received a single high dose of COMP360 psilocybin with psychological support showed an improvement in depressive symptom severity after three weeks